Literature DB >> 1991681

Radiation induction of drug resistance in RIF-1: correlation of tumor and cell culture results.

J E Moulder1, L E Hopwood, D M Volk, B M Davies.   

Abstract

The RIF-1 tumor line contains cells that are resistant to various anti-neoplastic drugs, including 5-fluorouracil (5FU), methotrexate (MTX), adriamycin (ADR), and etoposide (VP16). The frequency of these drug-resistant cells is increased after irradiation. The frequency of drug-resistant cells and the magnitude of radiation-induced drug resistance are different in cell culture than in tumors. The dose-response and expression time relationships for radiation induction of drug resistance observed in RIF-1 tumors are unusual. We hypothesize that at high radiation doses in vivo, we are selecting for cells that are both drug resistant and radiation resistant due to microenvironmental factors, whereas at low radiation doses in vivo and all radiation doses in vitro, we are observing true mutants. These studies indicate that there can be significant differences in drug-resistance frequencies between tumors and their cell lines of origin, and that radiation induction of drug resistance depends significantly on whether the induction is done in tumors or in cell culture. These results imply that theories about the induction of drug resistance that are based on cell culture studies may be inapplicable to the induction of drug resistance in tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991681     DOI: 10.1016/0360-3016(91)90092-i

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib.

Authors:  Saeid Afshar; Abdolazim Sedighi Pashaki; Rezvan Najafi; Safoora Nikzad; Razieh Amini; Nooshin Shabab; Omid Khiabanchian; Hamid Tanzadehpanah; Massoud Saidijam
Journal:  Iran J Med Sci       Date:  2020-01

2.  Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.

Authors:  W Budach; V Budach; M Stuschke; B Schmauder; P Reipke; M E Scheulen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.